EKF Diagnostics Holdings plc

AIM:EKF Stock Report

Market Cap: UK£113.4m

EKF Diagnostics Holdings Valuation

Is EKF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EKF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EKF (£0.26) is trading below our estimate of fair value (£0.57)

Significantly Below Fair Value: EKF is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EKF?

Key metric: As EKF is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EKF. This is calculated by dividing EKF's market cap by their current earnings.
What is EKF's PE Ratio?
PE Ratio24.4x
EarningsUK£4.78m
Market CapUK£113.43m

Price to Earnings Ratio vs Peers

How does EKF's PE Ratio compare to its peers?

The above table shows the PE ratio for EKF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.2x
NIOX NIOX Group
23.7x17.1%UK£260.3m
SN. Smith & Nephew
35.3x22.5%UK£8.6b
TSTL Tristel
32.3x17.5%UK£209.7m
IDHC Integrated Diagnostics Holdings
13.6x23.7%US$225.8m
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m

Price-To-Earnings vs Peers: EKF is good value based on its Price-To-Earnings Ratio (24.4x) compared to the peer average (26.2x).

Price to Earnings Ratio vs Industry

How does EKF's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EKF 24.4xIndustry Avg. 29.7xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EKF is good value based on its Price-To-Earnings Ratio (24.4x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is EKF's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EKF PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EKF's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EKF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.26
UK£0.34
+32.3%
10.5%UK£0.37UK£0.29n/a3
Nov ’25UK£0.27
UK£0.34
+25.9%
10.5%UK£0.37UK£0.29n/a3
Oct ’25UK£0.30
UK£0.34
+14.5%
10.5%UK£0.37UK£0.29n/a3
Sep ’25UK£0.28
UK£0.33
+19.3%
13.5%UK£0.37UK£0.27n/a3
Aug ’25UK£0.28
UK£0.33
+20.1%
13.5%UK£0.37UK£0.27n/a3
Jul ’25UK£0.28
UK£0.34
+21.6%
10.5%UK£0.37UK£0.29n/a3
Jun ’25UK£0.32
UK£0.34
+4.8%
10.5%UK£0.37UK£0.29n/a3
May ’25UK£0.31
UK£0.33
+8.6%
9.3%UK£0.36UK£0.29n/a3
Apr ’25UK£0.28
UK£0.33
+20.8%
9.3%UK£0.36UK£0.29n/a3
Mar ’25UK£0.27
UK£0.33
+19.0%
8.0%UK£0.35UK£0.29n/a3
Feb ’25UK£0.31
UK£0.33
+6.2%
8.0%UK£0.35UK£0.29n/a3
Jan ’25UK£0.32
UK£0.31
-2.8%
13.1%UK£0.35UK£0.25n/a4
Dec ’24UK£0.28
UK£0.31
+9.4%
13.1%UK£0.35UK£0.25n/a4
Nov ’24UK£0.29
UK£0.31
+8.4%
14.4%UK£0.35UK£0.25UK£0.273
Oct ’24UK£0.27
UK£0.35
+28.4%
23.6%UK£0.45UK£0.25UK£0.303
Sep ’24UK£0.27
UK£0.45
+64.8%
4.6%UK£0.47UK£0.42UK£0.283
Aug ’24UK£0.27
UK£0.45
+63.9%
4.6%UK£0.47UK£0.42UK£0.283
Jul ’24UK£0.32
UK£0.45
+41.8%
4.6%UK£0.47UK£0.42UK£0.283
Jun ’24UK£0.28
UK£0.45
+57.8%
4.6%UK£0.47UK£0.42UK£0.323
May ’24UK£0.28
UK£0.45
+59.5%
4.6%UK£0.47UK£0.42UK£0.313
Apr ’24UK£0.31
UK£0.46
+48.4%
2.2%UK£0.47UK£0.45UK£0.282
Mar ’24UK£0.29
UK£0.47
+60.3%
3.2%UK£0.48UK£0.45UK£0.272
Feb ’24UK£0.42
UK£0.72
+72.5%
23.6%UK£0.96UK£0.60UK£0.313
Jan ’24UK£0.50
UK£0.72
+44.0%
23.6%UK£0.96UK£0.60UK£0.323
Dec ’23UK£0.43
UK£0.72
+67.1%
23.6%UK£0.96UK£0.60UK£0.283
Nov ’23UK£0.46
UK£0.72
+56.5%
23.6%UK£0.96UK£0.60UK£0.293

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Guerbet

€339.2m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

7D

-9.8%

1Y

50.2%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.92

7D

-4.8%

1Y

-9.6%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.06

7D

-6.1%

1Y

5.3%